
    
      This is a single-arm, multicenter clinical study to evaluate efficacy and safety of chimeric
      antigen receptor T cell immunotherapy (CAR-T) in the treatment of relapsed or refractory
      neuroblastoma in children. The study will be conducted using a phaseⅠ/Ⅱdesign the study will
      have the following sequential phases: part A (screening, leukapheresis,cell product
      preparation and cytoreductive chemotherapy) and part B (treatment and follow-up). the
      follow-up period for each participant is approximately 35 months after the final CAR-T
      infusion. The total duration of the study are expected to be approximately 3 years. A total
      of 22 patients may be enrolled over a period of 3 years.
    
  